I am a
Home I AM A Search Login

Papers of the Week

Papers: 24 Sep 2022 - 30 Sep 2022

2022 Sep 29

Expert Rev Clin Immunol

An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.


Labib A, Yosipovitch G
Expert Rev Clin Immunol. 2022 Sep 29:1-12.
PMID: 36173402.


Atopic dermatitis (AD) is a common itchy inflammatory skin condition that affects many individuals. For many years, the landscape of AD treatment remained unchanged; however, there has been developing therapies that directly target the underlying immunological mechanism of AD. Janus kinase (JAK) inhibitors are small molecules that have shown anti-inflammatory and anti-itch effects in AD. Recently, abrocitinib, an oral JAK 1 inhibitor, was approved by the Food and Drug Administration for atopic dermatitis.